Gene expression data of sensitive, Docetaxel resistant and Paclitaxel resistant MDA-MB-231 Cells

The taxanes, namely Paclitaxel and Docetaxel, are important and widely used cancer chemotherapy drugs in the treatment of invasive and metastatic human breast cancer. Although treatment with the taxanes is beneficial to many patients, drug-responsive tumors in patients with metastatic breast cancer often display resistance to these drugs, either initially or over time following the continued administration of chemotherapy drugs. To investigate the patterns of cross-resistance with the taxane drugs and to identify potential mechanisms of resistance, we generated a series of MDA-MB-231 taxane resistant cell lines. We then used microarrays to determine gene expression differences between sensitive, Docetaxel and Paclitaxel resistant MDA-MB-231 cells. RNA isolated from three independent passages of sensitive, Docetaxel and Paclitaxel resistant cell lines and purified using the Qiagen RNeasy Mini Kit. Total RNA was processed and hybridized to Affymetrix Genechip HU133A arrays.

紫杉烷类（taxanes）化合物，即紫杉醇（Paclitaxel）与多西他赛（Docetaxel），是治疗侵袭性与转移性人类乳腺癌的重要且广泛应用的癌症化疗药物。尽管紫杉烷类治疗对多数患者有益，但转移性乳腺癌患者的药物敏感性肿瘤往往会对这类药物产生耐药性，既可能为原发性耐药，也可能在持续化疗给药后逐渐出现获得性耐药。为探究紫杉烷类药物的交叉耐药模式并明确潜在的耐药机制，我们构建了一系列MDA-MB-231紫杉烷耐药细胞系。随后我们利用基因芯片（microarrays）技术，检测敏感型、多西他赛耐药型与紫杉醇耐药型MDA-MB-231细胞之间的基因表达差异。我们从敏感型、多西他赛耐药型与紫杉醇耐药型细胞系的三个独立传代培养物中分离RNA，并使用Qiagen RNeasy Mini试剂盒对RNA进行纯化。将总RNA进行处理后，与Affymetrix Genechip HU133A基因芯片进行杂交。